Migraine, Prophylactic Therapy ALD403 for Prophylaxis of frequent episodic Migraine

被引：0
|
作者：
Diener, H. C.
机构：
来源：
AKTUELLE NEUROLOGIE | 2015年 / 42卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [1] Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP Peptide Antibody in the Prevention of Frequent Episodic Migraine
    Goadsby, P. J.
    Dodick, D.
    Silberstein, S.
    Lipton, R. B.
    Olesen, J.
    Ashina, M.
    Wilks, K.
    Kudrow, D.
    Kroll, R.
    Kohrman, B.
    Bargar, R.
    Hirman, J.
    Smith, J.
    HEADACHE, 2014, 54 (08): : 1420 - 1420
  • [2] Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine
    Goadsby, Peter
    Dodick, David
    Silberstein, Stephen
    Lipton, Richard
    Olesen, Jes
    Ashina, Messoud
    Wilks, Kerri
    Kudrow, David
    Krolll, Robin
    Kohrman, Bruce
    Bargar, Robert
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2014, 83 (02) : E40 - E40
  • [3] Migraine Preventive Benefits of ALD403 (eptinezumab) begin in the first 24 Hours Following Intravenous Administration
    Goadsby, Peter J.
    Smith, Jeff
    Dodick, David
    Lipton, Richard
    Silberstein, Stephen
    Cady, Roger
    Hirman, Joe
    CEPHALALGIA, 2017, 37 : 38 - 39
  • [4] A Single Intravenous Administration of ALD403 (Eptinezumab) Reduces Use of Triptans Among Patients with Chronic Migraine
    Dodick, David
    Lipton, Richard
    Goadsby, Peter J.
    Silberstein, Stephen
    Cady, Roger
    Hirman, Joe
    CEPHALALGIA, 2017, 37 : 16 - 16
  • [5] ALD403 (eptinezumab) Elicits Meaningful Reductions in Migraine Activity 24 Hours After a Single Intravenous Administration
    Smith, J.
    Dodick, D. W.
    Goadsby, P. J.
    Silberstein, S. D.
    Lipton, R. B.
    Hirman, J.
    Cady, R.
    HEADACHE, 2017, 57 : 179 - 180
  • [6] Migraine, Prophylactic Therapy Filorexant in to the prophylactic Therapy of Migraine
    Diener, H. C.
    AKTUELLE NEUROLOGIE, 2015, 42 (05) : E67 - E67
  • [7] Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
    Dodick, David W.
    Goadsby, Peter J.
    Silberstein, Stephen D.
    Lipton, Richard B.
    Olesen, Jes
    Ashina, Messoud
    Wilks, Kerri
    Kudrow, David
    Kroll, Robin
    Kohrman, Bruce
    Bargar, Robert
    Hirman, Joe
    Smith, Jeff
    LANCET NEUROLOGY, 2014, 13 (11): : 1100 - 1107
  • [8] Erenumab for episodic migraine prophylaxis
    Overeem, Lucas Hendrik
    Neeb, Lars
    Reuter, Uwe
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 751 - 757
  • [9] Rational Design of a Monoclonal Antibody Inhibiting Calcitonin Gene-Related Peptide, ALD403 (eptinezumab), for the Prevention of Migraine
    Baker, B. B.
    Latham, J.
    HEADACHE, 2017, 57 : 175 - 176
  • [10] Migraine, Prophylactic Therapy No prophylactic Effect of Clopidogrel in Migraine
    Sprenger, T.
    AKTUELLE NEUROLOGIE, 2015, 42 (05) : E66 - E66
12345